Diabetes Drug Markets' Growth and Dominance

Sulfonylureas market in North America projected to grow from USD 3.05 billion in 2023 to around USD 3.35 billion by 2028, driven by increasing demand for effective diabetes management and the high incidence of diabetes in the US. Meanwhile, the China diabetes care drugs market is expected to reach USD 13.73 billion by 2028, with oral anti-diabetic drugs dominating the market. Additionally, the North America oral anti-diabetic drug market is projected to reach a valuation of USD 22.54 billion by 2028, with metformin maintaining its dominance.